content: <html>
  
  <head>
  
  
  
  
  
  </head>
  
  <body lang="EN-US">
  
  <div style="font-family:Times New Roman;">
  
  <div style="border:none;border-top:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;color:windowtext;margin:0in 0in .0001pt;padding:0in;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES
  AND EXCHANGE COMMISSION</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON,
  DC 20549</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT PURSUANT</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">TO SECTION&nbsp;13 OR 15(D)&nbsp;OF THE</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">Date
  of report (Date of earliest event reported) <b><font style="font-weight:bold;">April&nbsp;30</font>, 2008</b></font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="100%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:100.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Interleukin
    Genetics,&nbsp;Inc.</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="100%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:100.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of
    Registrant as Specified in Its Charter)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="100%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:100.0%;">
    <h6 style="border:none;color:windowtext;font-weight:bold;margin:0in 0in .0001pt;padding:0in;page-break-after:avoid;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;">Delaware</font></b></h6>
    </td>
   </tr>
   <tr>
    <td width="100%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:100.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(State or Other Jurisdiction</font><font size="2" style="font-size:10.0pt;">  <font style="letter-spacing:-.15pt;">of
    Incorporation)</font></font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">001-32715</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="color:windowtext;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;letter-spacing:-.15pt;">&nbsp;</font></b></p>
    </td>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">94-3123681</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(Commission File Number)</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;letter-spacing:-.15pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(IRS Employer Identification No.)</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">135 Beaver Street Waltham, MA</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="color:windowtext;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;letter-spacing:-.15pt;">&nbsp;</font></b></p>
    </td>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;letter-spacing:-.15pt;">02452</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(Address of Principal Executive Offices)</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;letter-spacing:-.15pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(Zip Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="100%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:100.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(781)
    398-0700</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="100%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:100.0%;">
    <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(</font><font size="2" style="font-size:10.0pt;">Registrant&#146;s
    Telephone Number, Including Area Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">(Former Name or Former Address,
  if Changed Since Last Report)</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;letter-spacing:-.15pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended
  to simultaneously satisfy the filing obligation of the registrant under any of
  the following provisions (<i>see </i>General
  Instruction A.2. below):</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160; Written communications pursuant to Rule&nbsp;425
  under the Securities Act (17 CFR 230.425)</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160; Soliciting material pursuant to Rule&nbsp;14a-12
  under the Exchange Act (17 CFR 240.14a-12)</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
  the Exchange Act (17 CFR 240.14d-2(b))</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;letter-spacing:-.15pt;">o</font><font size="2" style="font-size:10.0pt;letter-spacing:-.15pt;">&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
  the Exchange Act (17 CFR 240.13e-4(c))</font></p>
  
  <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;color:windowtext;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="color:windowtext;margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='',FILE='C:\JMS\rmoralec\08-13292-1\task2912317\13292-1-ba.htm',USER='rmoralec',CD='May  2 11:51 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 1.01&#160; ENTRY INTO A
  MATERIAL DEFINITIVE AGREEMENT.</font></b></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Effective
  as of April&nbsp;30, 2008, Interleukin Genetics,&nbsp;Inc. (the &#147;Company&#148;)
  entered into a one-year employment agreement with Eliot M. Lurier for the
  position of Chief Financial Officer that provides for automatic annual renewal
  terms.&#160; The agreement provides for a
  minimum annual base salary of $217,000, a sign-on bonus of up to $15,000
  payable following the first four months of employment and annual, discretionary
  bonuses of up to 30% of his base salary in effect during the year for which the
  bonus relates.&#160; Bonuses will be
  determined by the Compensation Committee of the Board of Directors upon the
  suggestion of the Chief Executive Officer and will be based upon the employee&#146;s
  performance and the overall performance of the Company for the year.&#160; Upon hire, Mr.&nbsp;Lurier will also be
  granted an option to purchase 40,000 shares of the Company&#146;s common stock at an
  exercise price equal to the closing price as reported on the American Stock Exchange
  on the grant date of the option.&#160; The
  option will vest in equal annual installments of 8,000 shares on each of the
  first five anniversaries of the grant date.</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
  agreement is terminable by (i)&nbsp;the Company with immediate effect if with
  cause or upon thirty days prior written notice if without cause, or (ii)&nbsp;Mr.&nbsp;Lurier
  upon thirty days prior written notice.&#160;
  If the Company terminates Mr.&nbsp;Lurier without cause and at any time
  following the three-month anniversary of April&nbsp;30, 2008, then the Company
  will pay Mr.&nbsp;Lurier, in addition to any accrued, but unpaid compensation
  prior to the termination, an amount equal to six months of his base salary in
  effect at the time of the termination and six months of continued healthcare
  coverage, to the same extent that the Company provided healthcare coverage
  during his employment, if Mr.&nbsp;Lurier elects to continue participation in
  the Company&#146;s health plans.&#160; The
  agreement further provides that Mr.&nbsp;Lurier will be prohibited, during his
  employment and for a period of six months following the termination of his
  employment, from accepting employment with or otherwise having an interest in a
  U.S.-based entity that develops and sells genetic testing products, from
  providing services to others that might conflict with the Company&#146;s interests
  or the Company&#146;s customers&#146; or clients&#146; interests, from sharing information or
  data pertaining to the Company&#146;s customers or clients with others, from
  soliciting or attempting to take away the Company&#146;s customers or clients, and
  from recruiting or attempting to recruit or hire or attempt to hire any
  employees of the Company.</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A
  copy of the Company&#146;s press release announcing Mr.&nbsp;Lurier&#146;s appointment,
  dated April&nbsp;30, 2008 is attached hereto as Exhibit&nbsp;99.1 and is
  incorporated herein by reference.</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM
  5.02&#160; DEPARTURE OF DIRECTORS OR PRINCIPAL
  OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.</font></b></p>
  
  <p style="color:windowtext;line-height:normal;margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
  disclosure provided under Item 1.01 above is incorporated herein by
  reference.&#160;&#160; Effective as of April&nbsp;30,
  2008, the Company&#146;s Board of Directors appointed Eliot M. Lurier, age 50, as
  Chief Financial Officer of the Company.&#160;
  Prior to joining the Company and since April&nbsp;2005, Mr.&nbsp;Lurier
  was Vice President, Finance and Administration and Chief Financial Officer of
  Nucryst Pharmaceuticals (NASDAQ:NCST, TSX:NCS), which he assisted in its
  initial public offering and where he was responsible for the company&#146;s
  reporting to the Securities and Exchange Commission and the implementation of
  Sarbanes-Oxley requirements. From April&nbsp;2004 to March&nbsp;2005, Mr.&nbsp;Lurier
  served as Chief Financial Officer and Chief Operating Officer for Bridge
  Pharmaceuticals,&nbsp;Inc., where he established policies for managing business
  operations. From 1983 to 2004, Mr.&nbsp;Lurier held a number of senior-level
  financial positions, including Chief </font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  
  <div style="color:windowtext;margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\rmoralec\08-13292-1\task2912317\13292-1-ba.htm',USER='rmoralec',CD='May  2 11:51 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div style="font-family:Times New Roman;">
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial
  Officer of Admetric Biochem,&nbsp;Inc., and Chief Financial Officer, Treasurer
  and Vice President of Finance of Ascent Pediatrics,&nbsp;Inc.&#160; From 1981 to 1983, Mr.&nbsp;Lurier was an auditor
  at Coopers and Lybrand in Boston, MA.&#160; He earned a B.S. in Accounting from
  Syracuse University in 1980 and is a Certified Public Accountant in
  Massachusetts.</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ITEM 9.01&#160; FINANCIAL
  STATEMENTS AND EXHIBITS.</font></b></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Exhibit.</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Press Release dated April&nbsp;30,
  2008.</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>
  
  <div style="color:windowtext;margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\rmoralec\08-13292-1\task2912317\13292-1-ba.htm',USER='rmoralec',CD='May  2 11:51 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the
  requirements of the Securities Exchange Act of 1934, the registrant has duly
  caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="color:windowtext;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="55%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:55.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Interleukin
    Genetics,&nbsp;Inc.</font></u></b></p>
    </td>
   </tr>
   <tr>
    <td width="55%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:55.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant)</font></p>
    </td>
   </tr>
   <tr>
    <td width="55%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:55.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="55%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:55.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:
    May&nbsp;2, 2008</font></p>
    </td>
    <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">/s/ LEWIS H. BENDER</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lewis H. Bender</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Chief Executive Officer</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="20%" valign="top" style="padding:0in 0in 0in 0in;width:20.0%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.56%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.44%;">
    <p style="color:windowtext;margin:0in -.1in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Signature)</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="color:windowtext;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>
  
  <div style="color:windowtext;margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\rmoralec\08-13292-1\task2912317\13292-1-ba.htm',USER='rmoralec',CD='May  2 11:51 2008' -->
  
  
  </body>
  
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "a08-13292_18k.htm", "description": "8-K", "secsgml_size_bytes": 30209}]
metadata_filer: {"company-data": {"conformed-name": "INTERLEUKIN GENETICS INC", "cik": "0001037649", "assigned-sic": "2835", "irs-number": "943123681", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32715", "film-number": "08797675"}, "business-address": {"street1": "135 BEAVER ST", "city": "WATHAM", "state": "MA", "zip": "02452", "phone": "1-781-398-0700"}, "mail-address": {"street1": "135 BEAVER ST", "city": "WATHAM", "state": "MA", "zip": "02452"}, "former-company": {"former-conformed-name": "MEDICAL SCIENCE SYSTEMS INC", "date-changed": "19971003"}}
text: UNITED STATES
  SECURITIES
  AND EXCHANGE COMMISSION
  WASHINGTON,
  DC 20549
  FORM 8-K
  CURRENT REPORT PURSUANT
  TO SECTION 13 OR 15(D) OF THE
  SECURITIES EXCHANGE ACT OF 1934
  Date
  of report (Date of earliest event reported)
  April 30
  , 2008
  Interleukin
    Genetics, Inc.
  (Exact Name of
    Registrant as Specified in Its Charter)
  Delaware
  (State or Other Jurisdiction
  of
    Incorporation)
  001-32715
  94-3123681
  (Commission File Number)
  (IRS Employer Identification No.)
  135 Beaver Street Waltham, MA
  02452
  (Address of Principal Executive Offices)
  (Zip Code)
  (781)
    398-0700
  (
  Registrant's
    Telephone Number, Including Area Code)
  (Former Name or Former Address,
  if Changed Since Last Report)
  Check the appropriate box below if the Form 8-K filing is intended
  to simultaneously satisfy the filing obligation of the registrant under any of
  the following provisions (
  see
  General
  Instruction A.2. below):
  o
  Written communications pursuant to Rule 425
  under the Securities Act (17 CFR 230.425)
  o
  Soliciting material pursuant to Rule 14a-12
  under the Exchange Act (17 CFR 240.14a-12)
  o
  Pre-commencement communications pursuant to Rule 14d-2(b) under
  the Exchange Act (17 CFR 240.14d-2(b))
  o
  Pre-commencement communications pursuant to Rule 13e-4(c) under
  the Exchange Act (17 CFR 240.13e-4(c))
  ITEM 1.01  ENTRY INTO A
  MATERIAL DEFINITIVE AGREEMENT.
  Effective
  as of April 30, 2008, Interleukin Genetics, Inc. (the "Company")
  entered into a one-year employment agreement with Eliot M. Lurier for the
  position of Chief Financial Officer that provides for automatic annual renewal
  terms.  The agreement provides for a
  minimum annual base salary of $217,000, a sign-on bonus of up to $15,000
  payable following the first four months of employment and annual, discretionary
  bonuses of up to 30% of his base salary in effect during the year for which the
  bonus relates.  Bonuses will be
  determined by the Compensation Committee of the Board of Directors upon the
  suggestion of the Chief Executive Officer and will be based upon the employee's
  performance and the overall performance of the Company for the year.  Upon hire, Mr. Lurier will also be
  granted an option to purchase 40,000 shares of the Company's common stock at an
  exercise price equal to the closing price as reported on the American Stock Exchange
  on the grant date of the option.  The
  option will vest in equal annual installments of 8,000 shares on each of the
  first five anniversaries of the grant date.
  The
  agreement is terminable by (i) the Company with immediate effect if with
  cause or upon thirty days prior written notice if without cause, or (ii) Mr. Lurier
  upon thirty days prior written notice. 
  If the Company terminates Mr. Lurier without cause and at any time
  following the three-month anniversary of April 30, 2008, then the Company
  will pay Mr. Lurier, in addition to any accrued, but unpaid compensation
  prior to the termination, an amount equal to six months of his base salary in
  effect at the time of the termination and six months of continued healthcare
  coverage, to the same extent that the Company provided healthcare coverage
  during his employment, if Mr. Lurier elects to continue participation in
  the Company's health plans.  The
  agreement further provides that Mr. Lurier will be prohibited, during his
  employment and for a period of six months following the termination of his
  employment, from accepting employment with or otherwise having an interest in a
  U.S.-based entity that develops and sells genetic testing products, from
  providing services to others that might conflict with the Company's interests
  or the Company's customers' or clients' interests, from sharing information or
  data pertaining to the Company's customers or clients with others, from
  soliciting or attempting to take away the Company's customers or clients, and
  from recruiting or attempting to recruit or hire or attempt to hire any
  employees of the Company.
  A
  copy of the Company's press release announcing Mr. Lurier's appointment,
  dated April 30, 2008 is attached hereto as Exhibit 99.1 and is
  incorporated herein by reference.
  ITEM
  5.02  DEPARTURE OF DIRECTORS OR PRINCIPAL
  OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
  The
  disclosure provided under Item 1.01 above is incorporated herein by
  reference.   Effective as of April 30,
  2008, the Company's Board of Directors appointed Eliot M. Lurier, age 50, as
  Chief Financial Officer of the Company. 
  Prior to joining the Company and since April 2005, Mr. Lurier
  was Vice President, Finance and Administration and Chief Financial Officer of
  Nucryst Pharmaceuticals (NASDAQ:NCST, TSX:NCS), which he assisted in its
  initial public offering and where he was responsible for the company's
  reporting to the Securities and Exchange Commission and the implementation of
  Sarbanes-Oxley requirements. From April 2004 to March 2005, Mr. Lurier
  served as Chief Financial Officer and Chief Operating Officer for Bridge
  Pharmaceuticals, Inc., where he established policies for managing business
  operations. From 1983 to 2004, Mr. Lurier held a number of senior-level
  financial positions, including Chief
  2
  Financial
  Officer of Admetric Biochem, Inc., and Chief Financial Officer, Treasurer
  and Vice President of Finance of Ascent Pediatrics, Inc.  From 1981 to 1983, Mr. Lurier was an auditor
  at Coopers and Lybrand in Boston, MA.  He earned a B.S. in Accounting from
  Syracuse University in 1980 and is a Certified Public Accountant in
  Massachusetts.
  ITEM 9.01  FINANCIAL
  STATEMENTS AND EXHIBITS.
  (d)
  Exhibit.
  99.1         Press Release dated April 30,
  2008.
  3
  SIGNATURE
  Pursuant to the
  requirements of the Securities Exchange Act of 1934, the registrant has duly
  caused this report to be signed on its behalf by the undersigned hereunto duly
  authorized.
  Interleukin
    Genetics, Inc.
  (Registrant)
  Date:
    May 2, 2008
  /s/ LEWIS H. BENDER
  Lewis H. Bender
  Chief Executive Officer
  (Signature)
  4